Omidenepag Promising Against Glaucoma in Real-World Study

Omidenepag Promising Against Glaucoma in Real-World Study

Eye drops containing 0.002% omidenepag isopropyl can safely reduce intraocular pressure in patients with newly diagnosed primary open-angle glaucoma, according to a real-world study.

Gene Therapy Reduces Ocular Pressure in a Mouse Model of Glaucoma

The progressive blindness of glaucoma arises from pressure damage to the retina, the proximate cause being the presence of too much aqueous humor in the eye. The underlying causes are more complex and less well understood. As is the case for raised blood pressure, however, there are any number of ways to influence relevant mechanisms in order to control pressure without actually addressing the root cause damage and dysfunction of aging. Here, fo…

TRPV4 activation by TGFβ2 enhances cellular contractility and drives ocular hypertension

The risk for developing primary open-angle glaucoma (POAG) correlates with the magnitude of ocular hypertension (OHT) and the concentration of transforming growth factor-β2 (TGFβ2) in the aqueous humor. Effective treatment of POAG requires a detailed understanding of the interaction between pressure sensing mechanisms in the trabecular meshwork (TM) and biochemical risk factors. Here, we employed molecular, optical, electrophysiological, and ton…